Drugs / Aclidinium bromide/formoterol fumarate
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT03181880 Comparator | Dec 2017 → Dec 2018 | chronic obstructive pulmonary disease | AstraZeneca | Withdrawn | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Aclidinium bromide/formoterol fumarate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03181880 ↗ |
| Route | Inhaled | “Each inhaler will contain at least 60 doses (and a maximum of 68 doses) of aclidinium bromide/formoterol fixed-dose combination 400μg /12μg.” NCT03181880 ↗ |